Prognostic role of plasma galectin-3 levels in acute coronary syndrome

Aim: Cystatin C, neutrophil gelatinase-associated lipocalin and galectin-3 have emerged as biomarker candidates to predict cardiovascular outcomes and mortality in the general population as well as in patients with coronary artery or renal disease. However, their predictive role and clinical utility...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal. Acute cardiovascular care 2020-12, Vol.9 (8), p.869-878
Main Authors: Obeid, Slayman, Yousif, Nooraldaem, Davies, Allan, Loretz, Ruben, Saleh, Lanja, Niederseer, David, Noor, Husam A, Amin, Haitham, Mach, François, Gencer, Baris, Räber, Lorenz, Windecker, Stephan, Templin, Christian, Nanchen, David, Rodondi, Nicolas, Muller, Olivier, Matter, Christian M, von Eckardstein, Arnold, Lüscher, Thomas F
Format: Article
Language:English
Subjects:
Acute Coronary Syndrome - blood
Acute Coronary Syndrome - mortality
Biomarkers - blood
Blood Proteins
Electrocardiography
Follow-Up Studies
Galectins - blood
Humans
Predictive Value of Tests
Prognosis
Registries
Risk Assessment - methods
Risk Factors
ROC Curve
Survival Rate - trends
Switzerland - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim: Cystatin C, neutrophil gelatinase-associated lipocalin and galectin-3 have emerged as biomarker candidates to predict cardiovascular outcomes and mortality in the general population as well as in patients with coronary artery or renal disease. However, their predictive role and clinical utility in patients with acute coronary syndromes alone or in combination beyond currently used risk scores remains to be determined. Methods and results: Cystatin C, neutrophil gelatinase-associated lipocalin, and galectin-3 were measured in plasmas of 1832 patients at the time of presentation with acute coronary syndromes requiring percutaneous coronary intervention or coronary artery bypass grafting. The primary outcomes were major adverse cardiac and cerebrovascular events (defined as the composite of all-cause mortality, cerebrovascular events, any repeat revascularization or myocardial infarction) and all-cause mortality after 1 year and occurred in 192 (10.5%) and 78 (4.3%) of patients, respectively. All three biomarkers were increased in those with major adverse cardiac and cerebrovascular events compared with those without (p
ISSN:2048-8726
2048-8734
DOI:10.1177/2048872620974612